Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128389 | 0.83 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL29723114 | 0.83 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL14236172 | 0.79 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL14128277 | 0.73 | SLC6A3 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11813056 | 0.71 | EIF2AK2 (0.39) | ALDH1A1ALOX15 | |
| SCHEMBL2265112 | 0.70 | ALOX15 (0.37) | NPC1MEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL1190815 | 0.70 | ALOX15 (0.37) | MEN1KMT2AALDH1A1ALOX15GAA | |
| SCHEMBL15610796 | 0.70 | MAPT (0.49) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL14235747 | 0.70 | MAPT (0.45) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL20643007 | 0.69 | SMN1; SMN2 (0.38) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714032-B1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORP (KR) | 2019-01-16 | — | — | EP | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-03-27 | — | — | US | disclosed |
| WO-2012165914-A2 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | NPC1 265/4885RAB9A 3188/4885MEN1 4040/4885 |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | NPC1 275/4885RAB9A 2951/4885MEN1 4390/4885 |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | NPC1 490/4885RAB9A 2217/4885MEN1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.